olivLaw · US equity research
LENSAR, Inc. LNSR
Surgical & Medical Instruments & Apparatus · SIC 3841 · Vertical: Surgical & Medical Instruments & Apparatus (SIC 3841)
LENSAR develops and markets laser systems for cataract treatment and corneal astigmatism, centred on its robotic ALLY system. Revenue grew 9% in fiscal 2025, and in the second quarter of 2026 the company reported positive net income, pointing to a shift toward a steadier recurring-revenue model.
At the close of 05 Nov 2026, LENSAR, Inc. (LNSR) stock was 5.50 USD (−5.82% on the day), with market capitalisation 67.6 m USD, beta 0.54, 52-week range 5.01–12.73 USD. Latest reported quarter (Q2 2026): revenue of 16.5 m USD (+18.4% YoY), net income of 3.5 m USD, diluted EPS 0.10 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 33.2
- weak (30–45)
- Bollinger (20, 2)
- 5.47 – 6.36
- in the lower half of the band · %B 0.03 · band width 15.0%
- SMA 50 / 200
- 6.84 / 7.34
- downtrend (price < SMA50 < SMA200)
- MACD (12, 26, 9)
- -0.29 / -0.30
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −17.9% | −1.1% | −16.8 pp | — |
| 3 months | −4.1% | −0.5% | −3.6 pp | — |
| 6 months | +5.2% | +4.4% | +0.8 pp | — |
| Year to date | −52.7% | +12.3% | −65.0 pp | — |
| 1 year | −56.1% | +13.5% | −69.6 pp | −39.9% |
| 3 years | +151.1% | +76.4% | +74.7 pp | −28.0% |
| 5 years | −24.1% | +63.7% | −87.8 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 13.5 m | 16.7 m | 14.2 m | 13.9 m | 14.3 m | 16.0 m | 13.4 m | 16.5 m |
| Cost of revenue | 7.3 m | 9.6 m | 7.0 m | 6.9 m | 8.3 m | 9.1 m | 7.0 m | 6.7 m |
| Research & development | 1.2 m | 1.3 m | 1.5 m | 1.4 m | 1.4 m | 1.3 m | 1.4 m | 1.3 m |
| SG&A | 6.1 m | 6.8 m | 11.1 m | 11.7 m | 12.0 m | 10.3 m | 2.5 m | 6.1 m |
| Operating income | -1.2 m | -1.3 m | -5.8 m | -6.3 m | -7.6 m | -4.9 m | 2.2 m | 2.1 m |
| Income tax | 0 | — | 0 | 0 | 0 | — | 0 | 0 |
| Net income | -1.5 m | -18.7 m | -27.3 m | -1.8 m | -3.7 m | -1.5 m | 36.3 m | 3.5 m |
| Diluted EPS | -0.13 | -1.61 ≈ | -2.32 | -0.15 | -0.31 | -0.12 ≈ | 0.00 | 0.10 |
| Operating cash flow | 3.2 m ≈ | 3.7 m | -6.9 m | -5.0 m ≈ | -3.5 m ≈ | 618.0 k | -4.3 m | -127.0 k ≈ |
| Capex | 20.0 k ≈ | 3.0 k | 6.0 k | 77.0 k ≈ | 0 ≈ | 0 | — | — |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 30.5 m | 26.4 m | 34.5 m | 35.4 m | 42.2 m | 53.5 m | 58.4 m |
| Revenue YoY | unavailable | −13.6% | +30.6% | +2.6% | +19.2% | +26.9% | +9.2% |
| Net income | -14.7 m | -19.8 m | -19.6 m | -19.9 m | -14.4 m | -31.4 m | -34.3 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | unavailable | unavailable | -2.09 | -1.96 | -1.31 | -2.73 | -2.87 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| net % | -48.0% | -75.0% | -56.9% | -56.3% | -34.1% | -58.7% | -58.7% |
| Free cash flow | -13.0 m | -14.2 m | -9.3 m | -15.0 m | -9.9 m | -2.4 m | -14.9 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 13.0 m USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- -26.0 m USD
- Total assets
- 71.4 m USD
- Debt / equity
- unavailable
- Current ratio
- 1.15x
- ROE
- unavailable
- ROA
- -49.8%
- FCF margin
- -25.5%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 26.4 m | 34.5 m | 35.4 m | 42.2 m | 53.5 m | 58.4 m | SEC (XBRL)· 31 Mar 2026verified |
| Cost of revenue | 12.3 m | 16.6 m | 15.4 m | 21.1 m | 27.6 m | 31.3 m | SEC (XBRL)· 31 Mar 2026verified |
| Gross profit | 14.1 m ≈ | 17.8 m ≈ | 20.0 m ≈ | 21.1 m ≈ | 25.9 m ≈ | 27.1 m ≈ | SEC (XBRL)· 31 Mar 2026derived |
| Research & development | 7.6 m | 12.4 m | 11.8 m | 6.1 m | 5.3 m | 5.6 m | SEC (XBRL)· 31 Mar 2026verified |
| SG&A | 23.8 m | 23.9 m | 27.2 m | 26.1 m | 26.5 m | 45.2 m | SEC (XBRL)· 31 Mar 2026verified |
| Operating income | -18.5 m | -19.7 m | -20.2 m | -12.2 m | -10.7 m | -24.6 m | SEC (XBRL)· 31 Mar 2026verified |
| Interest expense | 1.3 m | — | — | — | — | — | SEC (XBRL)· 12 Mar 2021verified |
| Pre-tax income | -19.8 m | -19.6 m | -19.9 m | -14.4 m | -31.4 m | -34.3 m | SEC (XBRL)· 31 Mar 2026verified |
| Net income | -19.8 m | -19.6 m | -19.9 m | -14.4 m | -31.4 m | -34.3 m | SEC (XBRL)· 31 Mar 2026verified |
| Diluted EPS | — | -2.09 | -1.96 | -1.31 | -2.73 | -2.87 | SEC (XBRL)· 31 Mar 2026verified |
| Weighted average diluted shares | — | 9.4 m | 10.2 m | 11.0 m | 11.5 m | 12.0 m | SEC (XBRL)· 31 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Revenue − Cost of revenue.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 40.6 m | 31.6 m | 14.7 m | 20.6 m | 16.3 m | 13.0 m | SEC (XBRL)· 31 Mar 2026verified |
| Receivables | 2.0 m | 4.6 m | 6.0 m | 4.0 m | 6.1 m | 6.4 m | SEC (XBRL)· 31 Mar 2026verified |
| Inventories | 13.5 m | 6.5 m | 11.7 m | 15.7 m | 11.4 m | 21.5 m | SEC (XBRL)· 31 Mar 2026verified |
| Current assets | 58.4 m | 44.8 m | 33.7 m | 46.4 m | 42.0 m | 46.8 m | SEC (XBRL)· 31 Mar 2026verified |
| Property, plant & equipment, net | 832.0 k | 756.0 k | 563.0 k | 679.0 k | 664.0 k | 505.0 k | SEC (XBRL)· 31 Mar 2026verified |
| Intangibles (excl. goodwill) | 12.1 m | 10.9 m | 12.1 m | 11.0 m | 6.1 m | 5.2 m | SEC (XBRL)· 31 Mar 2026verified |
| Total assets | 79.1 m | 66.5 m | 55.8 m | 69.6 m | 66.3 m | 71.4 m | SEC (XBRL)· 31 Mar 2026verified |
| Accounts payable | 2.5 m | 2.7 m | 5.4 m | 4.0 m | 6.0 m | 19.0 m | SEC (XBRL)· 31 Mar 2026verified |
| Current liabilities | 8.5 m | 8.7 m | 11.4 m | 11.6 m | 15.0 m | 40.6 m | SEC (XBRL)· 31 Mar 2026verified |
| Total liabilities | 11.9 m | 11.6 m | 13.9 m | 22.4 m | 47.7 m | 83.7 m | SEC (XBRL)· 31 Mar 2026verified |
| Equity | 67.2 m † | 54.9 m † | 42.0 m † | 33.4 m † | 4.9 m † | -26.0 m † | SEC (XBRL)· 31 Mar 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -13.8 m | -9.0 m | -14.9 m | -9.7 m | -2.3 m | -14.8 m | SEC (XBRL)· 31 Mar 2026verified |
| Capex | 366.0 k | 354.0 k | 115.0 k | 236.0 k | 156.0 k | 83.0 k | SEC (XBRL)· 31 Mar 2026verified |
| Free cash flow | -14.2 m ≈ | -9.3 m ≈ | -15.0 m ≈ | -9.9 m ≈ | -2.4 m ≈ | -14.9 m ≈ | SEC (XBRL)· 31 Mar 2026derived |
| Investing cash flow | -326.0 k | -354.0 k | -115.0 k | -4.2 m | -2.2 m | 1.3 m | SEC (XBRL)· 31 Mar 2026verified |
| Financing cash flow | 50.0 m | 361.0 k | -2.0 m | 19.8 m | 78.0 k | 10.3 m | SEC (XBRL)· 31 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 5 of at least 6
- score weight coverage: 33.3% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
05 Nov 2026Source: olivLaw, closing series
Market cap: 67.6 m USD
Key indicators
Coverage and freshness
Score by group
33% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · the reported interest expense is far older than the latest period (the filer changed its XBRL tag): a stale figure is not used
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 5 of at least 6; score weight coverage: 33.3% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | 57.6% | 100 (vs peers) | 19% |
| FCF conversion · Quality | -21.1% | 0 (on a fixed band) | 19% |
| Revenue CAGR 3Y · Growth | 18.2% | 100 (on a fixed band) | 25% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | 2.4x | 100 (on a fixed band) | 13% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -10.8% | 0 (on a fixed band) | 25% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet· partial100/100 · 1/3 factors with a value
- Growth· partial100/100 · 1/2 factors with a value
- Quality50/100 · 2/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial0/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
LENSAR, INC. (LNSR). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 58.4 m USD in 2025; YoY growth 9.2%; net margin 57.6%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 5 of at least 6; score weight coverage: 33.3% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Net margin: 57.6%
- Revenue CAGR 3Y: 18.2%
- Current ratio: 2.4x
What contradicts it
- FCF conversion: -21.1%
- FCF yield: -10.8%
Not assessed (insufficient data or a ratio without meaning): ROIC, EPS CAGR 3Y, Net debt / EBITDA, Interest coverage, P/E (TTM), EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Surgical & Medical Instruments & Apparatus (SIC 3841) · same industry (4-digit SIC) · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| SYKStryker Corp | 129.3 bn | 36.2 | 16.0% | 13.8% | +11.2% | −8% / +15% |
| MMM3m Company | 100.2 bn | 28.9 | 80.8% | 14.0% | +1.5% | +13% / +134% |
| BSXBoston Scientific Corporation | 66.4 bn | 19.4 | 14.3% | 16.6% | +19.9% | −55% / −18% |
| BDXBecton, Dickinson And Company | 57.0 bn | 63.2 | 3.8% | 4.0% | +8.2% | +37% / +13% |
| RMDResMed Inc. | 33.8 bn | 21.9 | 26.4% | 27.8% | +9.9% | −6% / +52% |
| DXCMDexcom, Inc. | 33.0 bn | 34.8 | 37.7% | 19.4% | +15.6% | +39% / −23% |
| WSTWest Pharmaceutical Services, Inc. | 28.5 bn | 45.9 | 21.2% | 18.8% | +6.3% | +47% / +17% |
| GMEDGlobus Medical, Inc. | 10.9 bn | 20.8 | 11.8% | 17.0% | +16.7% | −11% / +81% |
| PODDInsulet Corporation | 10.8 bn | 25.4 | 28.9% | 13.4% | +30.7% | −52% / −17% |
| TFXTeleflex Incorporated | 6.4 bn | — | -28.9% | -45.8% | +17.2% | +33% / −33% |
| MMSIMerit Medical Systems Inc | 5.4 bn | 33.7 | 9.8% | 9.9% | +11.8% | +3% / +25% |
| IRTCiRhythm Holdings, Inc. | 4.3 bn | — | -9.6% | -1.7% | +26.2% | −31% / +53% |
| ICUIIcu Medical Inc | 4.2 bn | 140.0 | 1.4% | 1.4% | −6.3% | +13% / +91% |
| NVCRNovoCure Limited | 1.6 bn | — | -35.2% | -16.8% | +8.3% | +6% / +10% |
| TNDMTandem Diabetes Care, Inc. | 1.3 bn | — | -48.0% | -6.1% | +7.9% | −14% / −11% |
| ATECAlphatec Holdings, Inc. | 1.2 bn | — | -1,888.0% | -10.3% | +25.0% | −65% / −34% |
| MDXGMimedx Group, Inc. | 478.6 m | — | -8.5% | -6.3% | +20.0% | −52% / −58% |
| SIShoulder Innovations, Inc. | 424.1 m | — | -151.9% | -58.3% | +49.6% | +32% / unavailable |
| BWAYBrainsway Ltd. | 415.5 m | 212.2 | 5.6% | 7.1% | +29.0% | +21% / +238% |
| SSIISs Innovations International, Inc. | 380.7 m | — | -26.1% | -23.7% | +105.7% | −72% / unavailable |
| CLPTClearPoint Neuro, Inc. | 278.6 m | — | -167.5% | -79.4% | +17.8% | −40% / +51% |
| TMCITreace Medical Concepts, Inc. | 271.8 m | — | -72.0% | -29.0% | +1.6% | +40% / −52% |
| PROFProfound Medical Corp. | 251.3 m | — | -73.5% | -171.6% | +50.7% | +4% / −37% |
| LUCDLucid Diagnostics Inc. | 79.3 m | — | -556.3% | -959.8% | +8.3% | −63% / −74% |
| MBOTMicrobot Medical Inc. | 71.9 m | — | -32.9% | — | unavailable | −56% / −15% |
1- and 3-year price returns: for LNSR from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | 62.10 Total return 1,029% · Per year 1,029% | 109.29 Total return 1,887% · Per year 1,887% | 163.94 Total return 2,881% · Per year 2,881% |
| 3 years | 73.66 Total return 1,239% · Per year 137% | 144.54 Total return 2,528% · Per year 197% | 236.07 Total return 4,192% · Per year 250% |
| 5 years | 87.38 Total return 1,489% · Per year 74% | 191.15 Total return 3,376% · Per year 103% | 339.94 Total return 6,081% · Per year 128% |
- Exit P/E± 36.13
- Net margin± 25.29
- Annual revenue growth± 18.86
- Annual dilution± 2.13
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
LENSAR develops and markets laser systems for cataract treatment and corneal astigmatism, centred on its robotic ALLY system. Revenue grew 9% in fiscal 2025, and in the second quarter of 2026 the company reported positive net income, pointing to a shift toward a steadier recurring-revenue model.
SWOT
Strengths
- The company has a growing installed base and a high share of recurring revenue, which gives relatively predictable revenue 13.
- The ALLY system is authorised in the US, the EU and several Asian countries, and its robotic automation is presented as a precision advantage 1.
- The second quarter of 2026 showed positive net income and revenue growth, suggesting improving operating efficiency 3.
Weaknesses
- The company has reported net losses over the period analysed and a significant accumulated deficit, which limits financial flexibility 1.
- Dependence on surgeon adoption and on patients willing to pay the difference makes revenue sensitive to economic conditions 1.
- Cash fell in the first half of 2026 compared with year-end 2025, and acquisition-related payables from the failed merger were large 13.
Opportunities
- Growth in cataract surgery volumes and wider laser adoption could expand the market available to the ALLY system 1.
- Expanding the US sales force and international distribution could increase new installations and procedure volumes 2.
- If the ALLY backlog converts into installations, recurring revenue could keep growing 3.
Threats
Risks
- Net losses and accumulated deficithigh
The company reported net losses in fiscal 2025 and an accumulated deficit, and profitability in the second quarter of 2026 does not guarantee these results will continue 13.
- Adoption of the ALLY systemhigh
Commercial success depends on further clearances and on surgeon and clinic acceptance; if adoption lags, revenue could fall short of expectations 1.
- Patient willingness to paymedium
Advanced procedures are not fully reimbursed, so patients must pay the difference, which could reduce volumes if economic conditions weaken 1.
- Supply chain and tariffsmedium
Some components come from single-source suppliers, and tariffs and inflation could raise costs or delay production 12.
- Aftermath of the terminated mergermedium
Ending the Alcon merger generated costs, possible litigation and a risk of losing staff or partners, with effects on operations still unclear 1.
Investment thesis
What would need to be true (bull case)
- If recurring revenue keeps growing and the ALLY backlog converts into installations, the company could sustain the profitability reported in the second quarter of 2026 3.
- The cataract laser market has substantial adoption potential, since only a small share of operations use a laser today 1.
- The US direct sales force and international distributors could support growth in the installed base and procedure volumes 2.
What would break the thesis
- The company has been loss-making in earlier years and carries an accumulated deficit, and the second-quarter profit could prove atypical 13.
- Revenue depends on patients willing to pay and on limited reimbursement, which could slow adoption of the ALLY system 1.
- Competitors with greater resources and pricing pressure could limit the company's market share 1.
What to watch
- Trajectory of recurring revenue and procedure volumeQ3 2026
- Conversion of the ALLY backlog into installationsQ4 2026
- Liquidity and management of payables from the terminated mergerQ4 2026
- New regulatory clearances for the ALLY system and expansion into new marketsnext 10-K
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
LENSAR is a commercial-stage medical device company that designs, develops and markets advanced laser systems for cataract treatment and for managing pre-existing or surgically induced corneal astigmatism 1. Its current systems are the LENSAR Laser System (LLS) and the ALLY Robotic Cataract Laser System, which combine advanced imaging, simplified procedure planning and a compact design for operating rooms and in-office surgical suites 1. The revenue model rests on selling or leasing systems plus consumables and procedure licences for each procedure, which creates a recurring revenue stream 1.
The ALLY system received FDA clearance in June 2022 and is available to surgeons in the US and EU, with regulatory clearance also in India, Taiwan, South Korea and other countries 1. The company sells through a direct US sales force and distributors in Europe and Asia, and manufactures its systems in Orlando, Florida 2. As of June 30, 2026 the installed base was about 445 systems, of which 215 were ALLY 3.
The merger agreement with Alcon announced in March 2025 was terminated in March 2026, with the company keeping a 10 million dollar cash deposit under a mutual release of claims 1. Acquisition-related costs were significant in 2025, and the company said it would reduce part of those payables in the first quarter of 2026 1.
Segments
System sales
Sales of new systems were a smaller part of revenue, at 12.1 million dollars in fiscal 2025 versus 13.3 million in fiscal 2024, and 2.8 million in the second quarter of 2026 13. This line is sensitive to installation pace and the ALLY backlog, which stood at 13 systems on June 30, 2026 3.
Market context
The global cataract treatment market is large and grows with an ageing population and new technologies, including laser systems and premium intraocular lenses 1. According to a report cited by the company, cataract surgeries could rise from 33.1 million in 2025 to 39.6 million in 2030, yet only about one million of them were performed with a laser in 2025 1.
Most cataract patients also have astigmatism, and a study cited by the company estimates that 70 to 90% of them present with addressable astigmatism before surgery 1. Third-party reimbursement remains limited for advanced procedures, so patients pay the difference, a factor that could slow adoption if demand weakens 1.
Trends
- Rising cataract surgery volumestailwind
An ageing population and projected growth in procedures through 2030 could support demand for cataract laser systems 1.
- Laser adoption in cataract surgerymixed
Only a small share of cataract operations use a laser today, leaving room to grow, but adoption depends on reimbursement and on patients willing to pay the difference 1.
- Inflation and supply chain pressureheadwind
Higher costs for materials, labour and transport, along with tariffs, have weighed on margins, and the company expects these pressures to continue for the foreseeable future 12.
- Lower surgeon reimbursementheadwind
The company notes that surgeon reimbursement for advanced procedures is declining and patients pay a significant share of the procedure cost, which could limit growth 1.
Competitive position
The cataract laser market includes competitors with longer operating histories, more diversified products and greater resources, which could pressure prices 1. The company argues that competing systems have limits in imaging, integration with preoperative devices and cataract density assessment 1.
LENSAR differentiates through its robotic automation, a compact footprint that fits the same operating room as phacoemulsification equipment, and a dual-modality laser that it describes as unique among commercial robotic systems 1. These advantages depend on the company's ability to persuade surgeons and clinics to adopt ALLY 1.
- Alcon
The company with which LENSAR agreed a merger, terminated in March 2026; the relationship is relevant to competitive positioning and to the mutual release agreement 1.
- Other cataract laser system makers
The filings refer to competitors generically as having more diversified products and greater resources, without naming specific entities in the sources provided 1.
- Premium intraocular lens makers
New lenses with complex optics could change demand for astigmatism-correction systems, a link the company points to in its filings 1.
- Ambulatory surgery centres and group purchasing organisations
These buyers can exert pricing pressure and shape how budgets are allocated, an indirect form of competition noted in the filings 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Quarterly report13 Aug 2026
- Current report13 Aug 2026Results of operations · Financial statements and exhibits
- Current report10 Aug 2026Shareholder vote
- Proxy statement23 Jun 2026
- Current report29 May 2026Departure or appointment of officers · Item 5.08 · Other events
- Quarterly report08 May 2026
- Current report08 May 2026Results of operations · Financial statements and exhibits
- Current report15 Apr 2026Departure or appointment of officers
- Annual report31 Mar 2026
- Current report31 Mar 2026Results of operations · Financial statements and exhibits
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / LENSAR, Inc. · 31 Mar 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / LENSAR, Inc. · 13 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / LENSAR, Inc. · 13 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.